Get started
Author

Friedrich Stölzel

Observed names: F Stölzel, F. Stolzel, F. Stölzel, Friedrich Stoelzel, Friedrich Stolzel, Friedrich Stölzel, Stolzel, F., Stölzel, Friedrich
Observed institutions: City Of Hope National Medical Center, German Cancer Research Center, Heidelberg University, University Hospital Heidelberg, Robert Bosch Hospital, Hospital Universitari i Politècnic La Fe, Christian-Albrechts-Universität zu Kiel, City of Hope, University Hospital Schleswig-Holstein, Universitäts Hautklinik Kiel, Universitätsklinikum Würzburg, University Hospital Carl Gustav Carus, Klinikum Chemnitz, Deutsche Knochenmarkspenderdatei, Nationales Centrum für Tumorerkrankungen Dresden, Deutsches Konsortium für Translationale Krebsforschung, German Cancer Research Center (DKFZ) Dresden, German Cancer Consortium (DKTK) Dresden, Technische Universität Dresden, University of Lübeck
ORCID: 0000-0003-0653-5332
Observed ORCID: 0000-0003-0653-5332
OpenAlex ID: A5047829491
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
2015 · R Zeiser, A Burchert, et al. · Leukemia · 539
New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management
2017 · on behalf of the Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group, Frank Kroschinsky, et al. · Critical Care · 500
PDF
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
2018 · Uwe Platzbecker, Jan Moritz Middeke, et al. · The Lancet Oncology · 346
Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium
2008 · M von Bonin, F Stölzel, et al. · Bone Marrow Transplantation · 306
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
2018 · Nimitha R Mathew, Francis Baumgartner, et al. · Nature Medicine · 295
Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System
2011 · Christoph Röllig, Martin Bornhäuser, et al. · Journal of Clinical Oncology · 265
Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia
2016 · Stefanie Göllner, Thomas Oellerich, et al. · Nature Medicine · 257
Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT
2019 · Maddalena Noviello, Francesco Manfredi, et al. · Nature Communications · 196
PDF
A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial
2010 · Christoph Röllig, Christian Thiede, et al. · Blood · 176
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
2021 · Franziska Taube, Julia Annabell Georgi, et al. · Blood · 163
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial
2019 · Dietrich Wilhelm Beelen, Rudolf Trenschel, et al. · The Lancet Haematology · 157
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
2020 · Jayakumar Vadakekolathu, Catherine Lai, et al. · Blood Advances · 154
PDF
18F-FDG-PET/CT for detection of extramedullary acute myeloid leukemia
2011 · F. Stolzel, C. Rollig, et al. · Haematologica · 134
PDF
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
2020 · Christoph Röllig, Michael Kramer, et al. · Blood · 133
PDF
Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts
2019 · Linus Angenendt, Christoph Röllig, et al. · Journal of Clinical Oncology · 115
PDF
Karyotype complexity and prognosis in acute myeloid leukemia
2016 · F Stölzel, B Mohr, et al. · Blood Cancer Journal · 106
PDF
Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1
2022 · Maike Janssen, Christina Schmidt, et al. · Blood · 102
PDF
Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis
2014 · Tobias Herold, Klaus H. Metzeler, et al. · Blood · 102
TP 53 mutation in patients with high‐risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation
2016 · Jan M. Middeke, Sylvia Herold, et al. · British Journal of Haematology · 98
PDF
Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome
2015 · Felix von Dalowski, Michael Kramer, et al. · Stem Cells · 94
PDF
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
2024 · Nico Gagelmann, Danai Dima, et al. · Journal of Clinical Oncology · 93
PDF
High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial
2013 · Markus Schaich, Stefani Parmentier, et al. · Journal of Clinical Oncology · 83
PDF
Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears
2022 · Jan-Niklas Eckardt, Tim Schmittmann, et al. · BMC Cancer · 82
PDF
Symptomatic central nervous system involvement in adult patients with acute myeloid leukemia
2017 · Nael Alakel, Friedrich Stölzel, et al. · Cancer Management and Research · 79
PDF
Allogeneic Stem-Cell Transplantation in Patients With NPM1-Mutated Acute Myeloid Leukemia: Results From a Prospective Donor Versus No-Donor Analysis of Patients After Upfront HLA Typing Within the SAL-AML 2003 Trial
2014 · Christoph Röllig, Martin Bornhäuser, et al. · Journal of Clinical Oncology · 79
PDF
Works count: 332
Citation count: 7,504
H-index: 44
I10-index: 110
Year
Topic
Type